There is still much to explore about the mechanisms of action of vitamin D, the potential use of synthetic analogs of it in new therapies, and its role in fighting infection, Gombart said. Since only primates and humans have the same biological pathways for use of vitamin D to regulate cathelicidin, studies have been constrained by the lack of appropriate animal models for research, he said. OSU scientists hope to address that by creation of a line of genetically modified mice that have some of these characteristics.
One compelling new study just done by researchers at the Intermountain Medical Center in Utah, and presented at a meeting of the American Heart Association, followed for more than a year nearly 28,000 patients ages 50 or older with no prior history of cardiovascular disease. It found that in patients with very low levels of vitamin D compared to those with normal levels 77 percent were more likely to die, 45 percent were more likely to develop coronary artery disease, and 78 percent were more likely to have a stroke.
|Contact: Adrian Gombart|
Oregon State University